EcoDrugPlus

Notch Receptor 3

Ensembl ID : ENSPEMG00000003368
Gene Symbol: NOTCH3
3 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSPEMG00000014947
Gene Symbol: NFKB2
3 Cross references
124 Possible Orthologues:

Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells 1, P105

Ensembl ID : ENSPEMG00000011360
Gene Symbol: NFKB1
1 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid Derived 2, Like 2

Ensembl ID : ENSPEMG00000023181
Gene Symbol: NFE2L2
1 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSPEMG00000019153
Gene Symbol: NR1H2
3 Cross references
305 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSPEMG00000018824
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSPEMG00000021973
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPEMG00000013692
Gene Symbol: NR3C2
3 Cross references
212 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1

Ensembl ID : ENSPEMG00000015909
Gene Symbol: NR3C1
1 Cross references
278 Possible Orthologues:

Nucleophosmin 1

Ensembl ID : ENSPEMG00000010032
Gene Symbol: NPM1
2 Cross references
130 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSPEMG00000016933
Gene Symbol: NOD2
1 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSPEMG00000007805
Gene Symbol: OPRD1
3 Cross references
252 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).